logo
Share SHARE
FONT-SIZE Plus   Neg

Basilea Announces Completion Of Toctino Transaction With Stiefel - Quick Facts

Basilea Pharmaceutica Ltd. (BPMUF.PK) said the transaction between Basilea Pharmaceutica International Ltd. and Stiefel, a GlaxoSmithKline(GSK, GSK.L) company, for Basilea's dermatology drug Toctino (alitretinoin) has been completed following antitrust approval and meeting other customary provisions.

Under the global agreement, Stiefel gains exclusive worldwide rights to Toctino as well as a license to know-how and assumes Basilea's existing distribution agreements for Toctino. Basilea receives an upfront payment of approximatelyCHF 225 million and will be eligible for a further milestone payment of up to GBP 50 million, related to a regulatory milestone of alitretinoin in the U.S.

In addition, Basilea will participate in future product sales in the U.S. through royalties starting three years after launch.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Federal Communications Commission Chairman Ajit Pai has announced plans to repeal the net neutrality rules implemented under President Barack Obama. Pai, who was appointed by President Donald Trump, said he circulated his draft order to his fellow FCC commissioners Tuesday morning, with the order... Reflecting expectations the House Republican tax reform bill would provide a relatively modest boost to economic growth, a new analysis by the Tax Policy Center found that the legislation would add about $1.3 trillion to the national debt over a decade. Uber has been hit with an $8.9 million civil penalty by Colorado for allegedly allowing drivers with questionable backgrounds to work for the ride-hailing company. The Colorado Public Utilities Commission or PUC said it has issued a Civil Penalty Assessment Notice or CPAN totaling $8.9 million to Rasier LLC, the parent company of Uber.
comments powered by Disqus
Follow RTT